Matches in SemOpenAlex for { <https://semopenalex.org/work/W2131637500> ?p ?o ?g. }
- W2131637500 endingPage "51" @default.
- W2131637500 startingPage "45" @default.
- W2131637500 abstract "Outcome of patients with acute myeloid leukemia (AML) who are older than 60 years of age remains unsatisfactory, with low remission rates and poor overall survival. We have previously established the activity of clofarabine plus cytarabine in AML relapse. We have now conducted a phase 2 study of clofarabine plus cytarabine in patients aged 50 years or older with previously untreated AML. Clofarabine was given at 40 mg/m2 as a 1-hour intravenous infusion for 5 days (days 2 to 6) followed 4 hours later by cytarabine at 1 g/m2/d as a 2-hour intravenous infusion for 5 days (days 1 to 5). Of 60 patients, 29 (48%) had secondary AML, 30 (50%) had abnormal karyotypes (monosomy 5 and/or 7 in 15 [25%]), and 11 (21%) showed FLT3 abnormalities. The overall response (OR) rate was 60% (52% CR, 8% CRp). Four patients (7%) died during induction. Adverse events were mainly grade 2 or lower and included diarrhea, nausea, vomiting, mucositis, skin reactions, liver test abnormalities, and infusion-related facial flushing and headaches. Myelosuppression was common. Clofarabine plus cytarabine has activity in adult AML, achieving a good CR rate. However, survival does not appear to be improved compared with other regimens. Modifications of this combination in AML therapy of older patients warrant further evaluation. (Blood. 2006;108:45-51)" @default.
- W2131637500 created "2016-06-24" @default.
- W2131637500 creator A5000750846 @default.
- W2131637500 creator A5011548707 @default.
- W2131637500 creator A5014102823 @default.
- W2131637500 creator A5015140142 @default.
- W2131637500 creator A5028026524 @default.
- W2131637500 creator A5028845635 @default.
- W2131637500 creator A5046097970 @default.
- W2131637500 creator A5061026876 @default.
- W2131637500 creator A5061285204 @default.
- W2131637500 creator A5077963154 @default.
- W2131637500 creator A5084290698 @default.
- W2131637500 creator A5085521139 @default.
- W2131637500 creator A5089428686 @default.
- W2131637500 creator A5090435894 @default.
- W2131637500 date "2006-07-01" @default.
- W2131637500 modified "2023-10-18" @default.
- W2131637500 title "Clofarabine and cytarabine combination as induction therapy for acute myeloid leukemia (AML) in patients 50 years of age or older" @default.
- W2131637500 cites W1484199726 @default.
- W2131637500 cites W1492609361 @default.
- W2131637500 cites W1534965621 @default.
- W2131637500 cites W201908734 @default.
- W2131637500 cites W2044041384 @default.
- W2131637500 cites W2054138461 @default.
- W2131637500 cites W2069298406 @default.
- W2131637500 cites W2070012795 @default.
- W2131637500 cites W2081947065 @default.
- W2131637500 cites W2102776788 @default.
- W2131637500 cites W2116171965 @default.
- W2131637500 cites W2124013844 @default.
- W2131637500 cites W2140291353 @default.
- W2131637500 cites W2148047805 @default.
- W2131637500 cites W2159256284 @default.
- W2131637500 cites W2162700652 @default.
- W2131637500 cites W2163334163 @default.
- W2131637500 cites W2188730531 @default.
- W2131637500 cites W2531484069 @default.
- W2131637500 cites W2568035963 @default.
- W2131637500 cites W2588062947 @default.
- W2131637500 cites W4244897830 @default.
- W2131637500 doi "https://doi.org/10.1182/blood-2005-08-3294" @default.
- W2131637500 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/16403905" @default.
- W2131637500 hasPublicationYear "2006" @default.
- W2131637500 type Work @default.
- W2131637500 sameAs 2131637500 @default.
- W2131637500 citedByCount "140" @default.
- W2131637500 countsByYear W21316375002012 @default.
- W2131637500 countsByYear W21316375002013 @default.
- W2131637500 countsByYear W21316375002014 @default.
- W2131637500 countsByYear W21316375002015 @default.
- W2131637500 countsByYear W21316375002016 @default.
- W2131637500 countsByYear W21316375002017 @default.
- W2131637500 countsByYear W21316375002018 @default.
- W2131637500 countsByYear W21316375002019 @default.
- W2131637500 countsByYear W21316375002020 @default.
- W2131637500 countsByYear W21316375002021 @default.
- W2131637500 countsByYear W21316375002022 @default.
- W2131637500 countsByYear W21316375002023 @default.
- W2131637500 crossrefType "journal-article" @default.
- W2131637500 hasAuthorship W2131637500A5000750846 @default.
- W2131637500 hasAuthorship W2131637500A5011548707 @default.
- W2131637500 hasAuthorship W2131637500A5014102823 @default.
- W2131637500 hasAuthorship W2131637500A5015140142 @default.
- W2131637500 hasAuthorship W2131637500A5028026524 @default.
- W2131637500 hasAuthorship W2131637500A5028845635 @default.
- W2131637500 hasAuthorship W2131637500A5046097970 @default.
- W2131637500 hasAuthorship W2131637500A5061026876 @default.
- W2131637500 hasAuthorship W2131637500A5061285204 @default.
- W2131637500 hasAuthorship W2131637500A5077963154 @default.
- W2131637500 hasAuthorship W2131637500A5084290698 @default.
- W2131637500 hasAuthorship W2131637500A5085521139 @default.
- W2131637500 hasAuthorship W2131637500A5089428686 @default.
- W2131637500 hasAuthorship W2131637500A5090435894 @default.
- W2131637500 hasBestOaLocation W21316375001 @default.
- W2131637500 hasConcept C126322002 @default.
- W2131637500 hasConcept C141071460 @default.
- W2131637500 hasConcept C197934379 @default.
- W2131637500 hasConcept C2776694085 @default.
- W2131637500 hasConcept C2777198975 @default.
- W2131637500 hasConcept C2778041864 @default.
- W2131637500 hasConcept C2778496288 @default.
- W2131637500 hasConcept C2778729363 @default.
- W2131637500 hasConcept C2780580376 @default.
- W2131637500 hasConcept C71924100 @default.
- W2131637500 hasConcept C90924648 @default.
- W2131637500 hasConceptScore W2131637500C126322002 @default.
- W2131637500 hasConceptScore W2131637500C141071460 @default.
- W2131637500 hasConceptScore W2131637500C197934379 @default.
- W2131637500 hasConceptScore W2131637500C2776694085 @default.
- W2131637500 hasConceptScore W2131637500C2777198975 @default.
- W2131637500 hasConceptScore W2131637500C2778041864 @default.
- W2131637500 hasConceptScore W2131637500C2778496288 @default.
- W2131637500 hasConceptScore W2131637500C2778729363 @default.
- W2131637500 hasConceptScore W2131637500C2780580376 @default.
- W2131637500 hasConceptScore W2131637500C71924100 @default.
- W2131637500 hasConceptScore W2131637500C90924648 @default.
- W2131637500 hasIssue "1" @default.